Novelix clearly differentiates itself from most startup biopharmaceutical companies through:
· NCE dermatology drug candidate with strong IP position that addresses most if not all competitor product deficiencies in the underserved and attractive actinic keratosis market
· Short timelines to next key valuation inflection point (human proof of concept)
· Secondary NCE program and full pipeline
· “Virtual Company Plus” business model enabling the company to advance programs with low cash burn